<DOC>
<DOCNO>EP-0623138</DOCNO> 
<TEXT>
<INVENTION-TITLE>
NEW ADENOSINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K317042	A61K317042	A61K3170	A61K3170	A61P2504	A61K317076	C07H19167	A61P4300	A61P2900	A61P900	C07H1916	A61K317052	C07H1900	A61P912	A61P4300	A61P2500	A61P2900	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61P	A61K	C07H	A61P	A61P	A61P	C07H	A61K	C07H	A61P	A61P	A61P	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61P25	A61K31	C07H19	A61P43	A61P29	A61P9	C07H19	A61K31	C07H19	A61P9	A61P43	A61P25	A61P29	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
UNION PHARMA SCIENT APPL
</APPLICANT-NAME>
<APPLICANT-NAME>
LABORATOIRES UPSA
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BRU-MAGNIEZ NICOLE
</INVENTOR-NAME>
<INVENTOR-NAME>
GUNGOR TIMUR
</INVENTOR-NAME>
<INVENTOR-NAME>
TEULON JEAN-MARIE
</INVENTOR-NAME>
<INVENTOR-NAME>
BRU-MAGNIEZ, NICOLE
</INVENTOR-NAME>
<INVENTOR-NAME>
GUNGOR, TIMUR
</INVENTOR-NAME>
<INVENTOR-NAME>
TEULON, JEAN-MARIE
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Adenosine derivatives characterised in that they are of general 
formula (I): 


 
in which: 


R
1
 represents a hydrogen atom, a halogen atom, a lower alkyl radical, a lower O-alkyl 
radical, a lower S-alkyl radical or a phenyl radical and can be located in the 

2-, 4-, 5-, 6- or 7-position of the indole; 
n is an integer from 0 to 4; 
R
2
 is a lower alkyl radical, a lower alkenyl radical, a lower alkynyl radical, a C
3
-C
7
-cycloalkyl 
radical or a lower O-alkyl radical; 
a phenyl or naphthyl radical which is unsubstituted or substituted by one to four 
identical or different substituents selected from a halogen atom, a nitro, lower 

alkyl, lower O-alkyl or lower S-alkyl group and a group -NR
7
R
8
, R
7
 and R
8
 
being a hydrogen atom or a lower alkyl radical;  

 
a heterocyclic radical selected from pyridine and thiophene which is 
unsubstituted or substituted by one to four identical or different substituents 

selected from a halogen atom and a nitro, lower alkyl, lower O- alkyl or lower S-alkyl 
group; 
or even, when n is equal to 2, 3 or 4, a group -NR
9
R
10
, R
9
 and R
10
 
simultaneously being a lower alkyl radical or forming, together with the nitrogen 

atom to which they are attached, a heterocycle selected from morpholine, 
piperidine and pyrrolidine; 
R
3
 and R
4
, which are identical or different, are a hydrogen atom or a lower alkyl 
radical; and 
R
5
 is a group -NHR
11
, R
11
 being a lower alkyl radical, a C
3
-C
7
-cycloalkyl 
radical, a lower alkyl chain possessing an alcohol or ether functional group, or 

even a group -(CH
2
)
n
-NR
9
R
10
, n, R
9
 and R
10
 being as defined above. 
Derivatives of general formula (I) according to claim 1, 
characterised in that: 


R
1
 is a hydrogen atom, a halogen atom, a lower alkyl radical, a lower O-alkyl 
radical, a lower S-alkyl radical or a phenyl radical and can be located in the 2- or 

5-position of the indole; 
n is an integer equal to 0, 1 or 2; 
R
2
 is a lower alkyl radical, a lower alkenyl radical, a lower alkynyl radical, a C
3
-C
7
-cycloalkyl 
radical or a lower O-alkyl radical; 
a phenyl or naphthyl radical which is unsubstituted or substituted by one or two 
identical or different substituents selected from a halogen atom, a nitro, lower 

alkyl or lower O-alkyl group and a group -NR
7
R
8
, R
7
 and R
8
 being a hydrogen 
atom or a lower alkyl radical; 
a heterocyclic radical selected from pyridine and thiophene which is 
unsubstituted or substituted by a halogen atom; 
or even, when n = 2, a group -NR
9
R
10
, R
9
 and R
10
 simultaneously being a 
lower alkyl radical or forming, together with the nitrogen atom to which they are 

attached, a heterocycle selected from morpholine, piperidine and pyrrolidine;  
 
R
3
 and R
4
, which are identical or different, are a hydrogen atom or a lower alkyl 
radical; and 
R
5
 is a group -NHR
11
, R
11
 being a lower alkyl radical, a C
3
-C
7
-cycloalkyl 
radical or a lower alkyl chain possessing an alcohol or ether functional group, 
Derivatives according to claim 1 or claim 2 characterised in that R
1
 
is a hydrogen atom or a radical selected from methyl or methoxy. 
Derivatives according to claim 1 or claim 2 characterised in that n is 
a number selected from 0, 1 or 2. 
Derivatives according to claim 1 or claim 2 characterised in that R
2
 
is a radical selected from methoxy, cyclopentane, isopropyl, 2,5-dimethylphenyl 

and piperidine. 
Derivatives according to claim 1 or claim 2 characterised in that R
3
 
is a hydrogen atom. 
Derivatives according to claim 1 or claim 2 characterised in that R
4
 
is a hydrogen atom or a methyl radical. 
Derivatives according to claim 1 or claim 2 characterised in that R
5
 
is an N-cyclopropylamine radical. 
Derivatives according to claim 1 or claim 2 characterised in that 
they are selected from the following derivatives: 


Methods of preparing the compounds of formula (I) according to 
any one of claims 1 to 9, characterised in that they comprise reacting an amine of 

the formula 

 
in which R
1
, R
2
, R
3
, R
4
 and n are as defined in claim 1 or claim 2, with the 6-halopurine 
ribosides of the formula 


 
in which X is a halogen atom, R
12
 is a group COR
5
, R
5
 being as defined in claim 
1 or claim 2, or the CH
2
OH group, and R
13
 and R
14
 are protecting groups such 
as, for example, acetyl, benzoyl or benzyl, or can together form another protecting 

group, for example of the dioxolan structure, in a solvent such as an alcohol or 
dimethylformamide, in the presence of a base such as triethylamine, pyridine or  

 
sodium, potassium or calcium carbonate, or even in the presence of two 

equivalents of the amine, at a temperature of between 20째 and 140째C, after which 
the alcohols will be deprotected by various methods known to those skilled in the 

art, namely in a basic medium with an ammoniacal alcohol solution, or in an acid 
medium with a normal hydrochloric acid solution or a formic acid solution, at a 

temperature varying from 0째 to 70째C depending on the nature of the protecting 
groups. 
A pharmaceutical composition characterised in that it comprises a 
pharmaceutically effective amount of at least one compound of formula (I) as 

defined in any one of claims 1 to 9, or one of its pharmaceutically acceptable 
addition salts, which may or may not be incorporated in a pharmaceutically 

acceptable excipient, vehicle or carrier. 
A pharmaceutical composition with analgesic activity, 
characterised in that it contains a pharmaceutically effective amount of at least one 

compound of formula (I) as defined in any one of claims 1 to 9, or one of its 
pharmaceutically acceptable addition salts, which may or may not be incorporated 

in a pharmaceutically acceptable excipient, vehicle or carrier. 
A pharmaceutical composition with antihypertensive activity, 
characterised in that it contains a pharmaceutically effective amount of at least one 

compound of formula (I) as defined in any one of claims 1 to 9, or one of its 
pharmaceutically acceptable addition salts, which may or may not be incorporated 

in a pharmaceutically acceptable excipient, vehicle or carrier. 
A method of preparing a pharmaceutical composition, 
characterised in that it comprises incorporating a pharmaceutically effective 

amount of at least one compound of formula (I) as defined in any one of claims 1 
to 9, or one of its pharmaceutically acceptable addition salts, into a 

pharmaceutically acceptable excipient, vehicle or carrier. 
A method according to claim 14, characterised in that the 
pharmaceutical composition is formulated as gelatine capsules or tablets 

containing from 5 to 300 mg of active ingredient, or as injectable preparations 
containing from 0.1 to 100 mg of active ingredient. 
</CLAIMS>
</TEXT>
</DOC>
